Strategic analysis
Internal audit
Improvement actions after review, to prevent recurrence
Calibration and process progress
Quality committee quality evaluation
INQUIRIES |
MicrobiotiX strives to develop treatments
for global intractable diseases such as
multidrug-resistant bacterial infections,
autoimmune diseases and cancer.
We develop bacteriophage and microbiome based therapy against superbugs
MicrobiotiX strives to develop treatments
for global intractable diseases such as
multidrug-resistant bacterial infections,
autoimmune diseases and cancer.
We develop bacteriophage and microbiome based therapy against superbugs |
MICROBIOTIX Microbiotics is a company that develops bacteriophage and microbiome based therapeutics targeting multidrug resistant pathogens. We aim to develop therapy for autoimmune diseases and various incurable diseases. We have the best technology in the field of bacteriophage, microbiome and a GMP facility for global advancement. More  |
MICROBIOTIX Microbiotics is a company that develops bacteriophage and microbiome based therapeutics targeting multidrug resistant pathogens. We aim to develop therapy for autoimmune diseases and various incurable diseases. We have the best technology in the field of bacteriophage, microbiome and a GMP facility for global advancement. More |
BACTERIOPHAGE
MICROBIOTIX
MicrobiotiX is developing a bacteriophage-based treatment to address the threat of multidrug-resistant bacteria. We are a venture company that possesses a bacteriophage library which has been collected and researched over 15 years. Our phage library includes 300 types of lytic bacteriophages that can target multidrug-resistant, gram-negative Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli. These bacterial strains are classified as the most urgent threat to global health by the World Health Organization (WHO) and the CDC.
BACTERIOPHAGE
MICROBIOTIX
MicrobiotiX is developing a bacteriophage-based treatment to address the threat of multidrug-resistant bacteria. We are a venture company that possesses a bacteriophage library which has been collected and researched over 15 years. Our phage library includes 300 types of lytic bacteriophages that can target multidrug-resistant, gram-negative Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli. These bacterial strains are classified as the most urgent threat to global health by the World Health Organization (WHO) and the CDC.
GMP FACILITY
Quality Control
GMP FACILITY
Quality Control
| INQUIRIES |